WuXi AppTec raised its full-year revenue guidance after its net profit surged 62.4 per cent in the first nine months of 2026, while revenue rose 38.6 per cent on strong demand for its drug development and manufacturing services.
The Chinese pharmaceutical research services provider’s net profit reached 19.16 billion yuan (US$2.87 billion) for the nine months ended September 30, compared with 11.80 billion yuan a year earlier, a filing to the Hong Kong stock exchange showed. Its revenue rose to 45.54 billion yuan from 32.86 billion yuan.
The Shanghai-based company raised its full-year revenue forecast to 61 billion to 61.9 billion yuan, from 58.5 billion to 60.5 billion yuan previously projected, according to the filing. Revenue from continuing operations was now expected to grow 40 per cent to 42 per cent, compared with its previous forecast of 35 per cent to 39 per cent.